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Bleeding has always been an alarming clinical symptom in
all human societies, and physicians have had varying
degrees of success in diagnosing and treating bleeding
patients [1]. Because bleeding is part of the human experi-
ence, one the most challenging tasks for a physician is to
discriminate between “normal” and “pathologic” bleeding.
Hemorrhages or bleeds may occur in every tissue and
organ. Every bleeding symptom may, however, vary greatly
in terms of magnitude: for instance bleeds in the subcuta-
neous tissues may present as small pinpoint lesions (pete-
chiae) or large bruises, and epistaxis may range from some
blood-streaked mucus to a massive hemorrhage [2]. Minor
bleeding is a broad category encompassing a wide variety
of symptoms that are, however, severe enough to interfere
with the patient’ everyday life. Major bleeding defines
those episodes that may cause permanent damage to the
patient or threaten his or her life. Major bleeding is
defined as bleeding in a critical area (intracranial, intrasp-
inal, intraocular, retroperitoneal, intra-articular or pericar-
dial, or intramuscular with compartment syndrome)
resulting in an hemoglobin fall > 2 g/dl or requiring trans-
fusion [3]. Bleeding in a child can be a diagnostic challenge
because of the wide range of causes, but making a specific
diagnosis is clinically important in order to provide appro-
priate therapy. Bleeding disorders can be inherited or
acquired, and include coagulation factor deficiencies or
Von Willebrand diseases, platelet deficiencies and/or dys-
functions, blood vessels alterations [4]. The evaluation of a
child presenting with bleeding should include a compre-
hensive medical and bleeding history, a complete family
history, a detailed examination and selected laboratory
tests. For immune thrombocytopenia, in newly diagnoses
children, intravenous human immunoglobulin or corticos-
teroids can be used [5]. Individuals with platelet function
defects should be managed by qualified specialist and pla-
telet inhibitor medication should be avoid. First line drugs
for patients with platelet dysfunction are: antifibrinolytics,
desmopressin, platelet transfusions and recombinant
factor VIIa [6,7]. Bleeding events still occurs in patients
with hemophilia despite prophylactic factor replacement.
Adequate management depends not only upon the hemo-
philia subtype and site of bleeding, but also the episode
severity, identifiable precipitants (e.g. trauma), the patients’
age and current place of residence, adequacy of venous
access, presence of inhibitors, previous history of bleeding,
and the time of onset in relation to prophylactic therapy.
For all diseases other important initial considerations
include the applicability of first aid measures (e.g ice,
direct pressure, splinting) and appropriate analgesia [8].
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